SCHEMBL7133281

SCHEMBL7133281

COc1c(C(=O)NCc2cccnc2)ccc2c1C=CS2(O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.59
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
TSHR P16473 2/20 0.56
BLM P54132 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
CYP2C19 P33261 1/20 0.55
GAA P10253 1/20 0.53
ALDH1A1 P00352 5/20 0.53
USP2 O75604 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
LMNA P02545 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAPT P10636 1/20 0.49
HPGD P15428 3/20 0.49
POLB P06746 2/20 0.49
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.48
PDE10A Q9Y233 1/20 0.48
SORT1 Q99523 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133284 0.91 RECQL (0.55) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL7128411 0.83 USP2 (0.58) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL7123841 0.81 ALDH1A1 (0.65) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL7129470 0.76 PLK1 (0.41) GAAALDH1A1LMNAHPGDKDM4E
SCHEMBL7128962 0.75 CYP1A2 (0.47) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL7123842 0.74 ALDH1A1 (0.64) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL2926787 0.74 ALDH1A1 (0.78) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL7134614 0.73 NAMPT (0.48) RECQLCYP1A2CYP3A4TSHRBLM
SCHEMBL7128416 0.73 USP2 (0.57) RECQLTSHRALDH1A1USP2NPSR1
SCHEMBL3180009 0.73 RECQL (0.64) RECQLCYP1A2CYP3A4TSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO RECQL 4179/4885CYP1A2 1294/4885CYP3A4 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.